For World Sight Day, Horizon & Prevent Blindness Are Calling on the Thyroid Eye Disease (TED) Community to Put “Vision Firs...
October 10 2019 - 9:00AM
Business Wire
-- Text the word “EYE” to 56512 to generate a
donation from Horizon to Prevent Blindness to fund TED education
--
Today, in support of World Sight Day, Horizon Therapeutics plc
(Nasdaq: HZNP) and Prevent Blindness launched a campaign that
brings together the voices of the thyroid eye disease (TED)
community to educate the public on how TED can damage vision and
encourage people who are living with TED to put their vision first
by sharing their experiences, monitoring their symptoms and finding
the right doctor. World Sight Day is an internationally recognized
awareness day designed to focus attention on blindness and vision
impairment. This year’s dialogue emphasizes “Vision First,” with a
call to the community to make vision a priority.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20191010005204/en/
Now through Oct. 31, 2019, Horizon will donate $1 (up to
$10,000) to Prevent Blindness every time someone texts “EYE” to
56512. The campaign also invites the TED community to visit
www.MyTEDStory.com to share how they have seen TED affect vision –
whether it be from experiencing it personally, or watching a
friend, loved one or patient endure it. Select stories will be
compiled and shared on social media to help people who are living
with TED, healthcare professionals and the general public better
understand the disease. Spotting the signs and symptoms of TED
early can help decrease the chances of permanent eye damage. People
who are at risk for TED, including those with Graves’ disease, are
encouraged to pay attention to changes in their eyes – such as
pain, redness, light sensitivity, bulging, blurry vision and double
vision – and visit an ophthalmologist or oculoplastic surgeon to
get an eye exam.
“According to the World Health Organization, approximately 80
percent of all vision impairment across the globe is considered
avoidable – this statistic is both shocking and unacceptable,” said
Jeff Todd, president and CEO, Prevent Blindness. “As a part of our
sight-saving mission, we are thrilled to partner with Horizon to
raise awareness about TED and inspire patients to actively monitor
and successfully manage their symptoms.”
TED is a serious, progressive and vision-threatening autoimmune
disease.1,2 TED begins with active TED that may last for up to
three years, after which damage to the eyes can be irreversible.1,3
Common symptoms include light sensitivity, eye grittiness, bulging
eyes and double vision, among others – all of which can reduce a
person’s independence, ability to work and self-confidence.1,4 As
TED progresses, it can cause long-term, irreversible damage.
Effective management of TED requires early diagnosis and active
monitoring to identify the best opportunity for medical
intervention.1 Patients who suspect that they may have TED should
visit an eye specialist, such as an ophthalmologist or oculoplastic
surgeon, to have their eyes examined. To learn more about TED,
visit the new Prevent Blindness web resource and visit
www.ThyroidEyes.com to sign up to receive information about
TED.
“At Horizon, we’ve made it our priority to better understand the
needs of the TED community,” said Matt Flesch, vice president,
communications and patient advocacy, Horizon. “Through
conversations with patients, caregivers and healthcare
professionals, we’ve heard how this disease can impair vision –
making it difficult to do the things we often take for granted,
like drive, walk up or down stairs alone and read. By working
together with Prevent Blindness, we hope to multiply our efforts
and reach even more people with the TED education and support they
need to speak up and be good advocates for their eye health.”
To learn more about World Sight Day and other ways to get
involved, visit the website for The International Agency for the
Prevention of Blindness.
About Prevent Blindness
Founded in 1908, Prevent Blindness is the nation's leading
volunteer eye health and safety organization dedicated to fighting
blindness and saving sight. Focused on promoting a continuum of
vision care, Prevent Blindness touches the lives of millions of
people each year through public and professional education,
advocacy, certified vision screening and training, community and
patient service programs and research. These services are made
possible through the generous support of the American public.
Together with a network of affiliates, Prevent Blindness is
committed to eliminating preventable blindness in America. For more
information, or to make a contribution to the sight-saving fund,
call 1-800-331-2020. Or, visit us on the Web at
preventblindness.org or facebook.com/preventblindness.
About Horizon
Horizon is focused on researching, developing and
commercializing medicines that address critical needs for people
impacted by rare and rheumatic diseases. Our pipeline is
purposeful: we apply scientific expertise and courage to bring
clinically meaningful therapies to patients. We believe science and
compassion must work together to transform lives. For more
information on how we go to incredible lengths to impact lives,
please visit www.horizontherapeutics.com, follow us @HorizonNews on
Twitter, like us on Facebook or explore career opportunities on
LinkedIn.
References
- Barrio-Barrio J, Sabater AL, Bonet-Farriol E,
Velazquez-Villoria A, Galofre JC. Graves’ Ophthalmopathy: VISA
versus EUGOGO Classification, Assessment, and Management. Journal
of Ophthalmology. 2015:1-16.
- Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ,
Marcocci C, Perros P, Salvi M, Wiersinga WM. The 2016 European
Thyroid Association/European Group on Graves' Orbitopathy
Guidelines for the Management of Graves' Orbitopathy. European
Thyroid Journal. 2016;5:9-26.
- Bothun ED, Scheurer RA, Harrison, AR, Lee, MS, Update on
thyroid eye disease and management. Clinical Ophthalmology.
2009;3:543-51.
- Ponto KA, Pitz S, Pfeiffer N, Hommel G, Weber MM, Kahaly GJ.
Quality of life and occupational disability in endocrine
orbitopathy. Dtsch Arztebl Int. 2009;106:283-299.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191010005204/en/
Contacts: Tina Ventura Senior Vice President,
Investor Relations Investor-relations@horizontherapeutics.com
Ruth Venning Executive Director, Investor Relations
Investor-relations@horizontherapeutics.com
U.S. Media Contact: Rachel Vann Associate
Director, Product Communications media@horizontherapeutics.com
Ireland Media Contact: Gordon MRM Ray Gordon
ray@gordonmrm.ie
Horizon Therapeutics Pub... (NASDAQ:HZNP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Horizon Therapeutics Pub... (NASDAQ:HZNP)
Historical Stock Chart
From Apr 2023 to Apr 2024